Olga Antonova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Olga Antonova has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Reymond
Center for Integrative Genomics, University of Lausanne
5 shared publications Alvaro Mendes
5 shared publicationsAndrew Read
Centre for Genomic Medicine, St Mary’s Hospital, Manchester, England
5 shared publications- Angus Clarke
Institute of Medical Genetics, Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK
5 shared publications Borut Peterlin
5 shared publications- Carla G. van El
Department of Human Genetics, Amsterdam UMC, location Vrije Universiteit, Amsterdam, the Netherlands.
5 shared publications
Latest Publications
- Open Access
- 2 August 2023
- Published by Medical University Prof. Dr. Paraskev Stoyanov - Varna in Annual for Hospital Pharmacy
- Vol. 9 (1) , 88-97
Genetic polymorphisms predisposing to common cardiovascular diseases
Genetic polymorphisms predisposing to common cardiovascular diseases
- 2 August 2023
- Published by Medical University Prof. Dr. Paraskev Stoyanov - Varna in Annual for Hospital Pharmacy
- Vol. 9 (1) , 88-97
Open AccessGenetic polymorphisms predisposing to common cardiovascular diseases
Genetic polymorphisms predisposing to common cardiovascular diseases
- Open Access
- 10 March 2023
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 37 (1)
Determination of expression level of AP1S1, CDK9, FIGF and HDAC11 genes in bladder tumors for aggressive phenotype characterization
- 10 March 2023
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 37 (1)
Open AccessDetermination of expression level of AP1S1, CDK9, FIGF and HDAC11 genes in bladder tumors for aggressive phenotype characterization
- Open Access
- 19 December 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 368
Correction to: Reply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’
- 19 December 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 368
Open AccessCorrection to: Reply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’
- Open Access
- 1 December 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 279-281
Reply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’
- 1 December 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 279-281
Open AccessReply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’
- Open Access
- 19 August 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (11) , 1306
Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
- 19 August 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (11) , 1306
Open AccessCorrection: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
- Open Access
- 1 April 2022
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 49 (1) , 17-21
The Role of Genetics in a Personalized Approach in Patients with Feeding Problems, Overweight and Obesity
Aim: For the last 20 years a large amount of data was gathered showing a genetic predisposition to overweight and obesity. The aim of this study was to demonstrate a personalized, genetic-based approach in normalizing the patients’ weight and eating habits. Materials and methods: Eight patients – seven women and one man – aged 28-51 years with BMI ranging from 17,58 to 38,95 kg/m 2 were examined. Two of them were underweight, two – with normal weight, two – overweight, and two – obese. Patients were genotyped for: APOA2 (rs5082), ADIPOQ, (rs17300539), FTO (rs9939609), KCTD10 (rs10850219), LIPC (rs1800588), MMAB (rs2241201), PPARG (rs1801282), ANKK1/DRD2 (rs1800497), TAS2R38 (rs1726866), LEPR (rs2025804) and SLC2A2 (rs5400). Based on the genetic results, the type of diet (balanced, Mediterranean, low-fat and low-carbohydrate) was determined; the predisposition to unhealthy eating habits was described and followed by a genetic counseling to clarify the findings as well as a dietitian consultation to formulate a personalized diet. Results: Our results showed that the patients’ actual diet was equivocally different from the genetically determined one. Аll patients, except for one, had hereditary predispositions to a particular unhealthy eating habit. Conclusion: The inclusion of genetic testing and personalization of the diet facilitates the long-term maintenance of optimal body weight.
- 1 April 2022
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 49 (1) , 17-21
Open AccessThe Role of Genetics in a Personalized Approach in Patients with Feeding Problems, Overweight and Obesity
Aim: For the last 20 years a large amount of data was gathered showing a genetic predisposition to overweight and obesity. The aim of this study was to demonstrate a personalized, genetic-based approach in normalizing the patients’ weight and eating habits. Materials and methods: Eight patients – seven women and one man – aged 28-51 years with BMI ranging from 17,58 to 38,95 kg/m 2 were examined. Two of them were underweight, two – with normal weight, two – overweight, and two – obese. Patients were genotyped for: APOA2 (rs5082), ADIPOQ, (rs17300539), FTO (rs9939609), KCTD10 (rs10850219), LIPC (rs1800588), MMAB (rs2241201), PPARG (rs1801282), ANKK1/DRD2 (rs1800497), TAS2R38 (rs1726866), LEPR (rs2025804) and SLC2A2 (rs5400). Based on the genetic results, the type of diet (balanced, Mediterranean, low-fat and low-carbohydrate) was determined; the predisposition to unhealthy eating habits was described and followed by a genetic counseling to clarify the findings as well as a dietitian consultation to formulate a personalized diet. Results: Our results showed that the patients’ actual diet was equivocally different from the genetically determined one. Аll patients, except for one, had hereditary predispositions to a particular unhealthy eating habit. Conclusion: The inclusion of genetic testing and personalization of the diet facilitates the long-term maintenance of optimal body weight.
- Open Access
- 14 March 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 628
Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
- 14 March 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 628
Open AccessCorrection: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
- Open Access
- 17 December 2021
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 493-495
The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.
- 17 December 2021
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 493-495
Open AccessThe use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 34 (1) , 506-514
Expression profiling of muscle invasive and non-invasive bladder tumors for biomarkers identification related to drug resistance, sensitivity and tumor progression
Many bladder cancer (BC) patients with early disease are asymptomatic and diagnosed at advanced stage when the therapeutic options are limited. This necessitates the development of reliable predictive molecular biomarkers that will ensure a positive therapeutic response in every patient. The aim of this study was to screen for alterations in gene expression levels related to drug sensitivity and resistance that may be further explored as potential predictive therapeutic biomarkers. Gene expression analysis of the 168 genes from two panels for Cancer drug resistance and metabolism (PAHS004) and Cancer Drug Targets (PAHS507z) was performed. A total of 47 transitorial cell bladder cancer samples of stage pTa, pT1, pT2 were investigated using the pooling method, which allows reducing the effect of biological variation and detecting only significant expression changes. Differential gene expression was calculated using the ΔΔCt method with GPDH as a housekeeping gene. The 4.0-fold change in gene expression was used as the cut-off threshold to determine upregulation or downregulation compared to normal bladder tissue (negative control). Significance of the differences in the expression profiles was assessed by nonparametric one-way analysis of variance (ANOVA) with Dunn’s multiple comparison tests and Mann-Witney test. We demonstrated a correlation of tumor invasion and several up-regulated genes related to chemotherapy resistance. For the first time, this study demonstrated overexpression of CDK8, CDK9, FIGF, HDAC11, IGF1 and PDGFRA genes in muscle-invasive bladder carcinomas. These genes and their proteins could be used as potential biomarkers for bladder cancer progression or prospective therapeutic targets.
- 1 January 2020
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 34 (1) , 506-514
Open AccessExpression profiling of muscle invasive and non-invasive bladder tumors for biomarkers identification related to drug resistance, sensitivity and tumor progression
Many bladder cancer (BC) patients with early disease are asymptomatic and diagnosed at advanced stage when the therapeutic options are limited. This necessitates the development of reliable predictive molecular biomarkers that will ensure a positive therapeutic response in every patient. The aim of this study was to screen for alterations in gene expression levels related to drug sensitivity and resistance that may be further explored as potential predictive therapeutic biomarkers. Gene expression analysis of the 168 genes from two panels for Cancer drug resistance and metabolism (PAHS004) and Cancer Drug Targets (PAHS507z) was performed. A total of 47 transitorial cell bladder cancer samples of stage pTa, pT1, pT2 were investigated using the pooling method, which allows reducing the effect of biological variation and detecting only significant expression changes. Differential gene expression was calculated using the ΔΔCt method with GPDH as a housekeeping gene. The 4.0-fold change in gene expression was used as the cut-off threshold to determine upregulation or downregulation compared to normal bladder tissue (negative control). Significance of the differences in the expression profiles was assessed by nonparametric one-way analysis of variance (ANOVA) with Dunn’s multiple comparison tests and Mann-Witney test. We demonstrated a correlation of tumor invasion and several up-regulated genes related to chemotherapy resistance. For the first time, this study demonstrated overexpression of CDK8, CDK9, FIGF, HDAC11, IGF1 and PDGFRA genes in muscle-invasive bladder carcinomas. These genes and their proteins could be used as potential biomarkers for bladder cancer progression or prospective therapeutic targets.